Bristol Myers Squibb will handle development, manufacturing and commercialization of the T-cell therapies. Prime Medicine ...

Prime Medicine shares rose on Monday after the company signed a research collaboration and license agreement Bristol Myers Squibb to develop reagents for T-cell therapies. In premarket trading ...

Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb ...

Prime Medicine has partnered with Bristol Myers Squibb to develop ex vivo T-cell therapies. BMS will pay $55 million up front and invest another $55 million, but the partnership could be worth ...

As announced this morning, Prime Medicine entered into a strategic research collaboration and license agreement with Bristol Myers Squibb, a global leader in cell therapy for hematology ...

On Monday, Prime Medicine (NASDAQ:PRME) received a reiterated Buy rating from TD Cowen, following the announcement of a significant collaboration with Bristol Myers (NYSE:BMY) Squibb (BMS ...

On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ...

Prime Medicine announced that it had signed a strategic research collaboration and license agreement with global pharmaceutical company Bristol Myers Squibb. The partnership will concentrate on ...

Prime Medicine will focus on the development ... the collaboration with Bristol Myers Squibb and the intended and potential benefits thereof, including the receipt of potential milestone and ...

As a result of this strategic pipeline prioritization, Prime Medicine will streamline its operating expenses and capital expenditures. Together with the $110 million upfront consideration received ...